JP2017129597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017129597A5 JP2017129597A5 JP2017069908A JP2017069908A JP2017129597A5 JP 2017129597 A5 JP2017129597 A5 JP 2017129597A5 JP 2017069908 A JP2017069908 A JP 2017069908A JP 2017069908 A JP2017069908 A JP 2017069908A JP 2017129597 A5 JP2017129597 A5 JP 2017129597A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- interleukin
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004127 Cytokines Human genes 0.000 claims 10
- 108090000695 Cytokines Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 230000002378 acidificating effect Effects 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102000003812 Interleukin-15 Human genes 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 102000003810 Interleukin-18 Human genes 0.000 claims 3
- 108090000171 Interleukin-18 Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000019355 Synuclein Human genes 0.000 claims 2
- 108050006783 Synuclein Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 102000003802 alpha-Synuclein Human genes 0.000 claims 1
- 108090000185 alpha-Synuclein Proteins 0.000 claims 1
- 102000003799 beta-Synuclein Human genes 0.000 claims 1
- 108090000182 beta-Synuclein Proteins 0.000 claims 1
- 102000004963 gamma-Synuclein Human genes 0.000 claims 1
- 108090001121 gamma-Synuclein Proteins 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110012983A KR20120093002A (ko) | 2011-02-14 | 2011-02-14 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
| KR10-2011-0012983 | 2011-02-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553044A Division JP6629497B2 (ja) | 2011-02-14 | 2012-02-10 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126244A Division JP2019207242A (ja) | 2011-02-14 | 2019-07-05 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017129597A JP2017129597A (ja) | 2017-07-27 |
| JP2017129597A5 true JP2017129597A5 (enExample) | 2017-09-07 |
| JP6798922B2 JP6798922B2 (ja) | 2020-12-09 |
Family
ID=46672988
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553044A Active JP6629497B2 (ja) | 2011-02-14 | 2012-02-10 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2017069908A Active JP6798922B2 (ja) | 2011-02-14 | 2017-03-31 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2019126244A Pending JP2019207242A (ja) | 2011-02-14 | 2019-07-05 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2021197948A Withdrawn JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2023076634A Active JP7660605B2 (ja) | 2011-02-14 | 2023-05-08 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553044A Active JP6629497B2 (ja) | 2011-02-14 | 2012-02-10 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126244A Pending JP2019207242A (ja) | 2011-02-14 | 2019-07-05 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2021197948A Withdrawn JP2022043119A (ja) | 2011-02-14 | 2021-12-06 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
| JP2023076634A Active JP7660605B2 (ja) | 2011-02-14 | 2023-05-08 | がんを診断する方法およびｎｋ細胞活性の測定を使用した診断キット |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11442069B2 (enExample) |
| EP (1) | EP2676139B1 (enExample) |
| JP (5) | JP6629497B2 (enExample) |
| KR (3) | KR20120093002A (enExample) |
| CN (1) | CN103370622B (enExample) |
| AU (2) | AU2012219184A1 (enExample) |
| BR (1) | BR112013020454B1 (enExample) |
| CA (1) | CA2826053C (enExample) |
| CL (1) | CL2013002361A1 (enExample) |
| DK (1) | DK2676139T3 (enExample) |
| EA (1) | EA038959B1 (enExample) |
| ES (1) | ES2797549T3 (enExample) |
| IL (1) | IL227952B (enExample) |
| MX (1) | MX361731B (enExample) |
| MY (1) | MY175351A (enExample) |
| RU (1) | RU2635194C2 (enExample) |
| SG (1) | SG192247A1 (enExample) |
| TW (2) | TWI668445B (enExample) |
| UA (1) | UA120697C2 (enExample) |
| WO (1) | WO2012110878A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120093002A (ko) | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
| US10509034B2 (en) | 2013-11-05 | 2019-12-17 | Agency For Science, Technology And Research | Bladder carcinoma biomarkers |
| JP6073417B2 (ja) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物 |
| KR101926166B1 (ko) * | 2016-05-24 | 2018-12-06 | 재단법인 아산사회복지재단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| WO2017204446A2 (ko) * | 2016-05-24 | 2017-11-30 | 울산대학교 산학협력단 | 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법 |
| CN106222140A (zh) * | 2016-08-04 | 2016-12-14 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞无血清培养基及其配制方法 |
| CN106085958A (zh) * | 2016-08-04 | 2016-11-09 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞的制备方法 |
| CN107686828A (zh) * | 2016-08-04 | 2018-02-13 | 英普乐孚生物技术(上海)有限公司 | 一种nk细胞无血清培养基 |
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR102090698B1 (ko) * | 2017-08-24 | 2020-04-23 | 연세대학교 산학협력단 | 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법 |
| NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| JP7649244B2 (ja) * | 2019-02-14 | 2025-03-19 | リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル | 免疫細胞の効力をアッセイするための刺激剤の使用 |
| WO2021041399A1 (en) * | 2019-08-29 | 2021-03-04 | Board Of Regents, The University Of Texas System | Cell cryopreservation medium |
| KR20220069018A (ko) * | 2019-09-25 | 2022-05-26 | 레토 래버러토리즈 컴퍼니 리미티드 | 재조합 인터류킨-15 유사체 |
| WO2021108389A1 (en) * | 2019-11-29 | 2021-06-03 | Nkmax Co., Ltd. | Method of producing natural killer cells and compositions thereof |
| CN113533729B (zh) * | 2021-06-15 | 2024-09-06 | 北京大学人民医院 | 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用 |
| CN118488963A (zh) * | 2021-12-17 | 2024-08-13 | 肯特大学 | 囊泡中生产重组生物分子的序列和方法 |
| KR20230156518A (ko) | 2022-05-06 | 2023-11-14 | (주)다이오진 | 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트 |
| CN115247149B (zh) * | 2022-08-22 | 2023-06-16 | 华域生物科技(天津)有限公司 | 适用于nk细胞的培养基组合物及培养方法 |
| CN115855779A (zh) * | 2023-01-18 | 2023-03-28 | 山东康华生物医疗科技股份有限公司 | 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| RU2153332C2 (ru) * | 1993-08-09 | 2000-07-27 | Орион Корпорейшн | Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами |
| DE69620877T2 (de) * | 1995-02-06 | 2002-12-12 | Genetics Institute, Inc. | Arzneimittelformulierungen für il-12 |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| JP3995248B2 (ja) | 2001-08-13 | 2007-10-24 | 準二郎 土山 | エプスタインバーウイルス陰性のｎｋ細胞株 |
| JP2005517389A (ja) * | 2001-11-20 | 2005-06-16 | アトゲン カンパニー リミティッド | 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質 |
| WO2003082206A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
| JP2004305095A (ja) | 2003-04-07 | 2004-11-04 | Limuloid Science Kk | 細胞活性化検出方法 |
| CN1297567C (zh) * | 2003-06-13 | 2007-01-31 | 马菁 | 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用 |
| ATE500267T1 (de) | 2003-07-21 | 2011-03-15 | Transgene Sa | Multifunktionelle cytokine |
| CA2533990A1 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| MXPA06005104A (es) | 2003-11-05 | 2007-01-25 | Palingen Inc | Citotoxicidad de celulas b aumentada en anticuerpos de enlace a cdim. |
| KR100565764B1 (ko) | 2005-05-02 | 2006-03-28 | (주)에이티젠 | 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질 |
| WO2005108423A1 (en) | 2004-05-11 | 2005-11-17 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| JP4653465B2 (ja) | 2004-10-25 | 2011-03-16 | 泰信 小林 | ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物 |
| EP1901766A2 (en) * | 2005-04-08 | 2008-03-26 | Morningside Venture Investments Limited | Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| EP2047246A4 (en) * | 2006-07-28 | 2009-11-04 | Univ New York State Res Found | METHOD AND KITS FOR MEASURING THE LYMPHOCYTE FUNCTION |
| WO2008070647A1 (en) * | 2006-12-07 | 2008-06-12 | Wyeth | Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample |
| AU2008204433B2 (en) | 2007-01-11 | 2014-03-13 | Novo Nordisk A/S | Anti-KIR antibodies, formulations, and uses thereof |
| EP2048237A1 (en) * | 2007-10-05 | 2009-04-15 | Avir Green Hills Biotechnology Research Development Trade Ag | Replication deficient Influenza virus for the expression of heterologous sequences |
| KR20120093002A (ko) | 2011-02-14 | 2012-08-22 | (주)에이티젠 | Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트 |
-
2011
- 2011-02-14 KR KR1020110012983A patent/KR20120093002A/ko active Pending
-
2012
- 2012-02-10 SG SG2013058375A patent/SG192247A1/en unknown
- 2012-02-10 MY MYPI2013002917A patent/MY175351A/en unknown
- 2012-02-10 RU RU2013141487A patent/RU2635194C2/ru active
- 2012-02-10 ES ES12747246T patent/ES2797549T3/es active Active
- 2012-02-10 EP EP12747246.2A patent/EP2676139B1/en active Active
- 2012-02-10 EA EA201391187A patent/EA038959B1/ru unknown
- 2012-02-10 CN CN201280008685.3A patent/CN103370622B/zh active Active
- 2012-02-10 AU AU2012219184A patent/AU2012219184A1/en not_active Abandoned
- 2012-02-10 MX MX2013009380A patent/MX361731B/es active IP Right Grant
- 2012-02-10 UA UAA201310947A patent/UA120697C2/uk unknown
- 2012-02-10 US US13/985,301 patent/US11442069B2/en active Active
- 2012-02-10 CA CA2826053A patent/CA2826053C/en active Active
- 2012-02-10 KR KR1020137006311A patent/KR101341538B1/ko active Active
- 2012-02-10 DK DK12747246.2T patent/DK2676139T3/da active
- 2012-02-10 BR BR112013020454-0A patent/BR112013020454B1/pt not_active IP Right Cessation
- 2012-02-10 JP JP2013553044A patent/JP6629497B2/ja active Active
- 2012-02-10 WO PCT/IB2012/000259 patent/WO2012110878A2/en not_active Ceased
- 2012-02-10 KR KR1020137031527A patent/KR101438573B1/ko active Active
- 2012-02-14 TW TW101104742A patent/TWI668445B/zh active
- 2012-02-14 TW TW106103526A patent/TWI681191B/zh not_active IP Right Cessation
-
2013
- 2013-08-14 IL IL227952A patent/IL227952B/en active IP Right Grant
- 2013-08-14 CL CL2013002361A patent/CL2013002361A1/es unknown
-
2017
- 2017-03-31 JP JP2017069908A patent/JP6798922B2/ja active Active
- 2017-04-20 AU AU2017202628A patent/AU2017202628B2/en not_active Ceased
-
2019
- 2019-07-05 JP JP2019126244A patent/JP2019207242A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197948A patent/JP2022043119A/ja not_active Withdrawn
-
2022
- 2022-03-10 US US17/691,391 patent/US12379384B2/en active Active
-
2023
- 2023-05-08 JP JP2023076634A patent/JP7660605B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017129597A5 (enExample) | ||
| Cameron et al. | Cytokines, chemokines and their receptors | |
| CN102796743B (zh) | 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因 | |
| Zenewicz et al. | Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation | |
| Xu et al. | Interleukin-17 and its expanding biological functions | |
| Cameron et al. | Cytokines and chemokines-their receptors and their genes: an overview | |
| CN110913871B (zh) | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 | |
| Akira | The role of IL-18 in innate immunity | |
| Pappu et al. | The interleukin‐17 cytokine family: critical players in host defence and inflammatory diseases | |
| Asahina et al. | A review of the roles of keratinocyte‐derived cytokines and chemokines in the pathogenesis of atopic dermatitis in humans and dogs | |
| Lazarevic et al. | T-bet: a bridge between innate and adaptive immunity | |
| CN112105633A (zh) | 新型白介素2及其用途 | |
| JP2019207242A5 (enExample) | ||
| RU2013141487A (ru) | Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток | |
| JP2017008109A5 (enExample) | ||
| Kim et al. | Downregulation of chicken interleukin-17 receptor A during Eimeria infection | |
| JP2019514373A5 (enExample) | ||
| JP2019506175A5 (enExample) | ||
| Lorè et al. | The IL-17A/IL-17RA axis in pulmonary defence and immunopathology | |
| Bougarn et al. | Staphylococcal-associated molecular patterns enhance expression of immune defense genes induced by IL-17 in mammary epithelial cells | |
| CN110050062A (zh) | 表达il12的溶瘤弹状病毒 | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| Bird et al. | Advances in fish cytokine biology give clues to the evolution of a complex network | |
| CN103509814A (zh) | 一种草鱼肿瘤坏死因子α基因的重组表达方法 | |
| Andoh et al. | Interleukin-17 augments tumor necrosis factor-α-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts |